GLP-1 agonists and changes in body mass and composition: a systematic review and meta-analysis

A meta-analysis pooling tirzepatide, semaglutide and dulaglutide trials reports the headline weight loss but also the body-composition concern: a meaningful fraction of the loss is lean skeletal muscle, not just fat. Lead with the muscle-loss number — this is the part the public framing has consistently glossed. The angle: the implications for older patients, sarcopenia risk, and why dose-tapering and resistance-training protocols should now be standard with GLP-1 prescriptions. Avoid hype; cite effect sizes and the heterogeneity across trials. Reader is medically literate and tired of glossy GLP-1 takes.